—
C+
C+ The full Closelook — membership. Open the C+ overview

GeneDx Holdings Corp. (WGS) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — GeneDx Holdings Corp.

WGS in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
GeneDx runs genetic testing services built around whole exome and whole genome sequencing, aimed mainly at diagnosing rare and paediatric disease. It also sells data and information services drawn from its sequencing work, and has built an AI-based platform that supports interpretation and clinical reporting for rare disease, hereditary risk and cancer tests. It is based in Stamford, Connecticut, and lists in the United States.
Where it sits in the stack
GeneDx carries no seat in our index; it sits in the Diagnostics & Research sleeve of our Healthcare universe, where sequencing volume and interpretation software rather than compute hardware set the pace.
Who it is priced against
Closelook's peer group does not name a comparison set for this stock; the name the market places alongside it is Natera, another genetic-testing company built on sequencing.
Why Closelook tracks it
GeneDx holds no seat in our index and carries no Closelook score, so the diary has not built a scored view of it and does not quote it in the editions.
What the diary watches
Whether the AI-based interpretation platform changes reporting turnaround or reimbursement for rare-disease and hereditary-risk tests, which would alter how the diary reads its sequencing volume.

GeneDx Holdings Corp. (WGS) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for WGS, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Diagnostics & Research · US · 8 names with week and year-to-date

Peer group

Diagnostics & Research · US

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against WGS on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is GeneDx Holdings Corp. (WGS)?

GeneDx Holdings Corp. trades as WGS on the US exchange (US) in the Closelook research universe, as of the registry build of 2026-09-18.

Is WGS in a Closelook index?

Not currently — GeneDx Holdings Corp. is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

Where does WGS trade against its moving averages?

Recovery attempt under the 200-day: Trades +36.9% vs the 50-day and +27.3% vs the 200-day average, 38.6% below the 52-week high and +225.8% off the 52-week low. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does GeneDx Holdings Corp. do?

GeneDx runs genetic testing services built around whole exome and whole genome sequencing, aimed mainly at diagnosing rare and paediatric disease. It also sells data and information services drawn from its sequencing work, and has built an AI-based platform that supports interpretation and clinical reporting for rare disease, hereditary risk and cancer tests. It is based in Stamford, Connecticut, and lists in the United States. Closelook's peer group does not name a comparison set for this stock; the name the market places alongside it is Natera, another genetic-testing company built on sequencing.

Where does GeneDx Holdings Corp. sit in the AI build-out?

GeneDx carries no seat in our index; it sits in the Diagnostics & Research sleeve of our Healthcare universe, where sequencing volume and interpretation software rather than compute hardware set the pace. GeneDx holds no seat in our index and carries no Closelook score, so the diary has not built a scored view of it and does not quote it in the editions.

What does this page show?

A live price chart with SMA overlays and drawing tools for WGS, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Diagnostics & Research. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.